Invega trinza and Hyperprolactinaemia - a phase IV clinical study of FDA data

Summary:

Hyperprolactinaemia is reported as a side effect among people who take Invega trinza (paliperidone palmitate), especially for people who are male, 30-39 old, also take Invega Sustenna, and have Schizophrenia.

The phase IV clinical study analyzes which people have Hyperprolactinaemia when taking Invega trinza. It is created by eHealthMe based on reports of 4,027 people who have side effects when taking Invega trinza from the FDA, and is updated regularly.

What is Invega trinza?

Invega trinza has active ingredients of paliperidone palmitate. eHealthMe is studying from 4,035 Invega trinza users. Check the latest studies of Invega trinza.

What is Hyperprolactinaemia?

Hyperprolactinaemia (abnormally high levels of prolactin in the blood) is found to be associated with 212 drugs and 392 conditions by eHealthMe. Check the latest studies of Hyperprolactinaemia.

On Aug, 04, 2026

4,027 people reported to have side effects when taking Invega trinza.
Among them, 13 people (0.32%) have Hyperprolactinaemia.

Could Invega trinza cause Hyperprolactinaemia?

Among these 13 people:

What is the gender of people who have Hyperprolactinaemia when taking Invega trinza? *

female: 9.09 %
male: 90.91 %

What is the age of people who have Hyperprolactinaemia when taking Invega trinza? *

What are other drugs people take besides Invega trinza? *

What are other side effects people have besides Hyperprolactinaemia? *

Weight Loss: 5 people, 38.46%
Akathisia (a movement disorder characterized by a feeling of inner restlessness): 4 people, 30.77%
Hyperlipidaemia (presence of excess lipids in the blood): 4 people, 30.77%
Seizures (abnormal excessive or synchronous neuronal activity in the brain): 3 people, 23.08%
Drug Ineffective: 3 people, 23.08%
Electrocardiogram Qt Prolonged: 3 people, 23.08%
Weight Increased: 3 people, 23.08%
High Blood Pressure: 3 people, 23.08%
Agranulocytosis (a deficiency of granulocytes in the blood, causing increased vulnerability to infection): 3 people, 23.08%
Type 2 Diabetes: 3 people, 23.08%

What are the existing conditions these people have? *

Schizophrenia (a mental disorder characterized by a breakdown of thought processes): 9 people, 69.23%
Depressive Symptom: 2 people, 15.38%
Bipolar Disorder (mood disorder): 2 people, 15.38%
Thinking Abnormal: 1 person, 7.69%
Stress And Anxiety: 1 person, 7.69%
Schizophreniform Disorder (mental disorder is diagnosed when the symptom criteria for schizophrenia are met, but the duration is too short and social and occupational functioning): 1 person, 7.69%
Panic Disorder: 1 person, 7.69%
Insomnia (sleeplessness): 1 person, 7.69%
High Blood Cholesterol: 1 person, 7.69%
Depression: 1 person, 7.69%

* Approximation only. Some reports may have incomplete information.

Do you take Invega trinza and have Hyperprolactinaemia?

- Check whether Hyperprolactinaemia is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Invega trinza:

Invega trinza (4,035 reports)

Browse all side effects of Invega trinza:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Hyperprolactinaemia:

Hyperprolactinaemia (212 drugs)

Browse all the conditions that are associated with Hyperprolactinaemia:

Hyperprolactinaemia (392 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on paliperidone palmitate (the active ingredients of Invega trinza) and Invega trinza (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.